Form 4: Director Nita Ahuja Receives Abbott Laboratories RSU Grant

Abbott Laboratories Director Nita Ahuja was granted 2,286 restricted stock units under the company's 2026 Incentive Stock Program.

Summary

• Director Nita Ahuja acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
• The grant was issued under the Abbott Laboratories 2026 Incentive Stock Program.
• The RSUs are payable in common shares on a one-to-one basis upon the director's separation from service, death, or a change in control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSUs will vest and be paid out upon the director's separation from service, death, or a change in control of the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice to ensure director alignment with long-term company performance in the healthcare and medical device sector.

Comparison to Industry Standards

• The grant structure is consistent with standard executive and director compensation packages among large-cap S&P 500 healthcare companies.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• No further action required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Insider Trading, Director Compensation, Restricted Stock Units